SpringWorks Expands Collaboration with GSK in Multiple Myeloma

 - SpringWorks to Receive $75 Million Equity Investment with Potential for an Additional $550 Million in Milestone Payments -

- SpringWorks to Supply Nirogacestat for GSK’s Global Blenrep Development Program and to Make Nirogacestat Commercially Available in Markets Where a Combination with Blenrep is Approved -

- SpringWorks to Continue Retaining Full Global Commercial Rights to Nirogacestat

https://finance.yahoo.com/news/springworks-announces-expansion-global-non-135500749.html